首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Frontiers In Immunology

Frontiers In Immunology杂志,由Frontiers Media S.A.出版,于2010年创刊,1 issue/year,出版语言English,ISSN:1664-3224,E-ISSN:1664-3224。

投稿咨询
Frontiers In Immunology
Frontiers In Immunology
Frontiers In Immunology
SCI SCIE

杂志介绍

JCR分区
Q1
中科院分区
2区
影响因子
7
CiteScore
11.3
期刊收录
SCI、SCIE

Frontiers In Immunology(中文译名:《免疫学前沿》),ISSN:1664-3224,EISSN:1664-3224,是Frontiers Media S.A.出版的国际性学术期刊,创刊于2010年,以1 issue/year形式稳定发行,2026年总发文量约6551篇。该刊采用OA开放访问,学科归属为IMMUNOLOGY。该刊是医学、免疫学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达7,2025年期刊CiteScore为11.3,2025年期刊自引率约7.1%,在中科院期刊分区体系中位列医学大类2区TOP 期刊,在所属学科领域具备高学术影响力与国际认可度。Frontiers In Immunology长期聚焦医学、免疫学及相关产业的技术应用前沿,平均审稿周期14 Weeks,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、免疫学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,USACHINA MAINLAND、GERMANY (FED REP GER)、England、Italy、France、Netherlands等为核心发文国家与地区;INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)、UNIVERSITY OF LONDON、HARVARD UNIVERSITY、UNIVERSITY OF CALIFORNIA SYSTEM、UNIVERSITY OF OXFORD、HELMHOLTZ ASSOCIATION等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
IMMUNOLOGY 免疫学
2区

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
IMMUNOLOGY 免疫学
2区

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
IMMUNOLOGY 免疫学
2区

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:IMMUNOLOGY SCIE Q1 29 / 183

84.4

学科:IMMUNOLOGY SCIE Q1 42 / 183

77.32

2023-2024年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:IMMUNOLOGY SCIE Q1 38 / 181

79.3

学科:IMMUNOLOGY SCIE Q1 43 / 181

76.52


中国学者近期发文

1
The glycolysis-lactylation axis: a metabolic-epigenetic driver of immunosuppression and therapy resistance in cance

Author:Tan, Simin; Zhang, Weijia; Ding, Yuqing; Liu, Jinlin; Zhu, Min; Luo, Xuefeng; Cai, Jun; Zeng, Hai

Journal: FRONTIERS IN IMMUNOLOGY. 2026; Vol. 17, Issue , pp. -. DOI: 10.3389/fimmu.2026.1772701

2
Biofilm adaptation and mucosal immune dysregulation in recalcitrant chronic rhinosinusitis: from pathogenesis to a therapeutic roadma

Author:Tan, Shiwang; Lai, Ju; Yu, Shaoqing

Journal: FRONTIERS IN IMMUNOLOGY. 2026; Vol. 17, Issue , pp. -. DOI: 10.3389/fimmu.2026.1797096

3
Efgartigimod as a potential alternative to intravenous immunoglobulin in Guillain-Barré syndrome: a retrospective stud

Author:Liu, Changyue; Wang, Kaiyue; Zhang, Shimeng; Gao, Naiyong; Xu, Guangyin; Qi, Faying

Journal: FRONTIERS IN IMMUNOLOGY. 2026; Vol. 17, Issue , pp. -. DOI: 10.3389/fimmu.2026.1734853

4
Efficacy and safety of efgartigimod in very-late-onset myasthenia gravi

Author:Zhao, Yunbin; Qu, Meijie; Rong, Xi; Sun, Xupeng; Wang, Li; Liu, Min; Sui, Jiaona

Journal: FRONTIERS IN IMMUNOLOGY. 2026; Vol. 17, Issue , pp. -. DOI: 10.3389/fimmu.2026.1808357

5
Overcoming immune resistance in hepatocellular carcinoma: insights into mechanisms, predictive factors, and interventional strategie

Author:Wang, Zhenxao; Wu, Jun; Li, Qiao; Wen, Xin

Journal: FRONTIERS IN IMMUNOLOGY. 2026; Vol. 17, Issue , pp. -. DOI: 10.3389/fimmu.2026.1804366

6
Case Report: Ultrasound features of pathological complete response in middle and low rectal cancer with high microsatellite instability after neoadjuvant immunotherapy: a case serie

Author:Liang, Li; Wang, Qi; Chen, Yifeng; Zhang, Xinhua; Zhou, Zubang; Nie, Fang

Journal: FRONTIERS IN IMMUNOLOGY. 2026; Vol. 17, Issue , pp. -. DOI: 10.3389/fimmu.2026.1772953

7
From centripetal to centrifugal: pathological regression patterns after neoadjuvant or conversion therapy as markers of nodal risk and a framework for future research on individualized lymphadenectomy in gastric cance

Author:Li, Na; Liu, Penghui; Guo, Jiwu; Wang, Jizhen; Zhao, Gengyutong; Mou, Ziyuan; Mao, Jie

Journal: FRONTIERS IN IMMUNOLOGY. 2026; Vol. 17, Issue , pp. -. DOI: 10.3389/fimmu.2026.1766242

8
Decoding the immune microenvironment: precision immunotherapy for medulloblastoma subtype

Author:Li, Mengyuan; Peng, Jihong; Chen, Chun; Hu, Jinyang

Journal: FRONTIERS IN IMMUNOLOGY. 2026; Vol. 17, Issue , pp. -. DOI: 10.3389/fimmu.2026.1714134

9
Durable response to FOLFOX plus serplulimab in AFP-producing gastric adenocarcinoma with liver metastases: a case report and literature revie

Author:Jin, Yuqi; Fu, Linglin; Zhao, Yuhan; Tong, Ziyan; Tan, Yinuo

Journal: FRONTIERS IN IMMUNOLOGY. 2026; Vol. 17, Issue , pp. -. DOI: 10.3389/fimmu.2026.1795732

10
Targeted regulation of adipose tissue macrophages from an immunometabolic perspective: a novel therapeutic approach for obesity-related metabolic disorder

Author:Jia, Chen; Wu, Enfang; Zhu, Chenjia; Guan, Xiyuan; Cheng, Yuqi; Zhao, Feng; Jin, Xin; Cao, Dan; Li, Xueyu

Journal: FRONTIERS IN IMMUNOLOGY. 2026; Vol. 17, Issue , pp. -. DOI: 10.3389/fimmu.2026.1803488


在线咨询

Frontiers In Immunology

国际简称:FRONT IMMUNOL参考译名:免疫学前沿

年发文量:6551 CiteScore:11.3 是否预警:否 Gold OA文章占比:99.90% 研究类文章占比:69.99%

杂志社联系方式:AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, SWITZERLAND, CH-1015

Frontiers In Immunology